ARTICLE
20 August 2024

Challenges In AI-Enabled Biomarker Discovery

FL
Foley & Lardner

Contributor

Foley & Lardner LLP looks beyond the law to focus on the constantly evolving demands facing our clients and their industries. With over 1,100 lawyers in 24 offices across the United States, Mexico, Europe and Asia, Foley approaches client service by first understanding our clients’ priorities, objectives and challenges. We work hard to understand our clients’ issues and forge long-term relationships with them to help achieve successful outcomes and solve their legal issues through practical business advice and cutting-edge legal insight. Our clients view us as trusted business advisors because we understand that great legal service is only valuable if it is relevant, practical and beneficial to their businesses.
Patient biomarkers are now used in personalized medicine to predict disease progression, minimize side effects, and maximize therapeutic benefits in the treatment of disease.
United States Technology
To print this article, all you need is to be registered or login on Mondaq.com.

Patient biomarkers are now used in personalized medicine to predict disease progression, minimize side effects, and maximize therapeutic benefits in the treatment of disease. In oncology, the use of biomarkers has increased treatment response rates from 20% to 42% when a biomarker is used in treatment decisions.2

Traditional biomarker discovery typically used a single quantifiable trait (for example, the presence of a genomic trait), which limits the ability to capture the intricate complexities of disease progression and response.2 In contrast, artificial intelligence (AI) and machine learning (ML) can source patients' medical history, genetic information, demographics, and lifestyle factors to analyze more data that may impact disease prediction, progression, and response.

Two recent reports1, 2 highlight the challenges of using AI and ML that rely on biomarker matching. Integration of large datasets sourced from different reference laboratories and clinical trials is complex, laborious and time-consuming.2 Added to that is the large volume of the data, requiring sophisticated tools to analyze and integrate the data, especially for complex diseases like cancer and autoimmune disorders.2 Also, because patient data is used, data security and privacy need to be taken into account.1 Moreover, there is the potential for bias at several levels: in the AI algorithms or training data, and potentially from the data collectors themselves.1 Finally, patients would have to accept and adopt the use of the technology, allowing their personal medical history and outcomes to be utilized to train and improve the algorithms.1

Unifying the storage of clinical data to simplify the training application of AI systems, and creation of uniform guidelines for the use of biomarker data could improve current systems.2 In addition, synergistic partnerships between investigative researchers and clinical practitioners could support the ethical use of the technology and support the discovery of biomarkers that are directly relevant to clinical practice. While challenges remain, there is no doubt that AI is transforming the delivery of health care and advancing personalized medicine.

Footnotes

1. Li et al. (2024), Innovation and Challenges of Artificial Intelligence Technology in Personalized Healthcare, https://doi.org/10.1038/s41598-024-70073-7.

2. Cioffi, M. and Nicks, B. (2024) The role of AI in Predictive Biomarker Patient Matching, https://endpts.com/sp/the-role-of-ai-in-predictive -biomarker-patient-matching/.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More